Login to Your Account



DUX in a row: Fulcrum bid in FSHD, fragile X garners Third Rock $55M series A

By Randy Osborne
Staff Writer

Tuesday, July 19, 2016

Saying "the time is right to bring all the various pieces together," Fulcrum Therapeutics Inc. CEO Robert Gould said his firm, funded by a $55 million series A round from Third Rock Ventures LLC, will combine recent findings in the biology of gene regulation to develop small-molecule therapies.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription